Long-term surveillance of patients with multiple sclerosis to report progressive multifocal leukoencephalopathy and other serious opportunistic infections among patients treated with natalizumab

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  National MS registry ReMuS Czechia
• Data sources (types):
  Other
• Data sources (types), other:
  The aim of the study is to characterise the safety profile of natalizumab in a routine clinical practice in the Czech Republic by monitoring serious adverse events (SAEs).

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No